BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31147301)

  • 1. The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations.
    Cogen JD; Whitlock KB; Gibson RL; Hoffman LR; VanDevanter DR
    J Cyst Fibros; 2019 Nov; 18(6):851-856. PubMed ID: 31147301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
    Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
    Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
    [No Abstract]   [Full Text] [Related]  

  • 3. Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.
    VanDevanter DR; Heltshe SL; Hilliard JB; Konstan MW
    J Cyst Fibros; 2021 Mar; 20(2):257-263. PubMed ID: 32505525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.
    Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nelson M; Nichols DP; Rosenfeld M; VanDevanter DR; Gibson RL
    Ann Am Thorac Soc; 2020 Dec; 17(12):1590-1598. PubMed ID: 32726564
    [No Abstract]   [Full Text] [Related]  

  • 5. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
    Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
    J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
    Thornton CS; Caverly LJ; Kalikin LM; Carmody LA; McClellan S; LeBar W; Sanders DB; West NE; Goss CH; Flume PA; Heltshe SL; VanDevanter DR; LiPuma JJ
    Ann Am Thorac Soc; 2024 Apr; 21(4):595-603. PubMed ID: 37963297
    [No Abstract]   [Full Text] [Related]  

  • 7. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
    VanDevanter DR; Morris NJ; Konstan MW
    J Cyst Fibros; 2016 May; 15(3):372-9. PubMed ID: 26603642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
    West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
    J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
    Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
    Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
    Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
    Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.
    VanDevanter DR; Pasta DJ; Konstan MW
    J Cyst Fibros; 2015 Nov; 14(6):763-9. PubMed ID: 25754096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of pulmonary exacerbation treatment in cystic fibrosis.
    Sanders DB; Ostrenga JS; Rosenfeld M; Fink AK; Schechter MS; Sawicki GS; Flume PA; Morgan WJ
    J Cyst Fibros; 2020 May; 19(3):407-414. PubMed ID: 31257102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
    Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
    Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
    Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
    BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
    VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
    J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).
    Gold LS; Patrick DL; Hansen RN; Goss CH; Kessler L
    J Cyst Fibros; 2019 Nov; 18(6):886-893. PubMed ID: 31126901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correspondence between symptoms and preference-based health status measures in the STOP study.
    Gold LS; Patrick DL; Hansen RN; Beckett V; Goss CH; Kessler L
    J Cyst Fibros; 2019 Mar; 18(2):251-264. PubMed ID: 30170756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhinovirus-associated pulmonary exacerbations show a lack of FEV1 improvement in children with cystic fibrosis.
    Cousin M; Molinari N; Foulongne V; Caimmi D; Vachier I; Abely M; Chiron R
    Influenza Other Respir Viruses; 2016 Mar; 10(2):109-12. PubMed ID: 26493783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
    McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH
    Ann Am Thorac Soc; 2024 May; 21(5):716-726. PubMed ID: 38096105
    [No Abstract]   [Full Text] [Related]  

  • 20. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.
    Wagener JS; Williams MJ; Millar SJ; Morgan WJ; Pasta DJ; Konstan MW
    J Cyst Fibros; 2018 Jul; 17(4):496-502. PubMed ID: 29685810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.